Does Medication Adherence Lead to Lower Healthcare Expenses for Patients With Diabetes? | Page 1
Published Online: August 13, 2013
Shou-Hsia Cheng, PhD; Chi-Chen Chen, PhD; and Chin-Hsiao Tseng, MD, PhD
Diabetes is a prevalent health condition that is associated with significant morbidity and mortality.1 In Taiwan and other countries, the prevalence and incidence of diabetes have been increasing over the past decade.2-4 This increase imposes a substantial economic burden on the healthcare system.5,6 Improving glycemic control may delay the onset and hamper the progression of macrovascular and microvascular complications associated with diabetes.7 Long-term glycemic control can be effectively managed through dietary control and lifestyle changes, but adherence to prescribed medication is the most influential aspect of diabetes management.8
An improvement in medication adherence may lead to better glycemic control,9 which, in turn, may reduce complications and healthcare utilization, such as the likelihood of hospitalization and emergency department (ED) visits. Asche et al (2011) summarized the findings of empirical studies and concluded that better medication adherence is associated with improved glycemic control and decreased healthcare service utilization.10 In addition, several researchers have reported that increasing adherence to oral antihyperglycemic medications may actually increase the expenses of these medications11-13 and decrease the expenses for other healthcare services, such as expenses for diabetesrelated hospitalizations or ED visits.11-13 However, whether the higher drug expenses would be offset by the reduction in healthcare expenses of other healthcare services is still controversial.10,14
The present study adds to the growing body of literature in 3 ways. First, most of the studies use observational designs which are subject to the problem of endogeneity, due to the healthy user effect13 or healthy adherer bias.15 If certain observed or unobserved characteristics of patients are related to both the medication adherence and their outcomes and expenses of healthcare services, then the characteristics may bias the result of the study. A typical example is that patients who are adherent to their medications are healthier and are more likely to adopt a healthy lifestyle, which may result in lower healthcare utilization and expenses irrespective of the effects of medication adherence. This study employed a multi-year longitudinal design to account for unobserved time-invariant characteristics of patients and to ensure the temporality of the association.16 Furthermore, in the sensitivity analysis section, we used a propensity score matching (PSM) approach to reduce the potential differences in the observed characteristics of patients between the adherent group and the nonadherent group for minimizing possible selection bias.17
Second, the majority of previous studies have only conducted short-term follow-up analyses.11,12,18-21 Therefore, there is limited evidence regarding the long-term effects of adherence to oral antihyperglycemic medications on the outcomes and expenses of healthcare.22,23 A longitudinal design may clarify whether medication adherence has different effects on healthcare expenses during the different duration of diabetes, which is currently unknown. Finally, this study focused on newly diagnosed patients only; therefore, the results might exclude the cumulative effects of adherence that occurred prior to the study period. A similar sample selection was used by Hong and Kong (2011).23
Medication adherence is closely associated with the healthcare system. The majority of studies concerning the relationship between medication adherence and the outcomes and expenses of healthcare have been conducted in the United States. Existing evidence shows that higher prescription cost-sharing reduces medication adherence, due to financial barriers.24,25 In recent years, a number of employers have implemented the policy of value-based insurance design (VBID). This policy encourages medication adherence for patients with chronic diseases by reducing their medication copayment.26
Taiwan’s National Health Insurance (NHI) program was launched in 1995 and provides a comprehensive benefits package to the public with a low drug cost-sharing requirement. 27 The outpatient prescription drug copayment was either zero or up to US$6, depending on the expenses of the prescribed medication for each physician visit (in 2009, NT$33 = US$1). Financial barriers to accessing prescribed medications should only be a minor concern in Taiwan compared with in the United States. Therefore, medication adherence in Taiwan should be less confounded by the ability of patients to afford the medication. Through the use of a longitudinal study design, this study aimed to examine the relationship between medication adherence and healthcare outcomes and expenses for adult patients with newly diagnosed type 2 diabetes mellitus (T2DM). Furthermore, this study also examined whether the duration of diabetes may play a role in the aforementioned relationship.
Data and Study Sample
The NHI claim data set for this study was obtained from the National Health Research Institutes of Taiwan. Using the NHI claims data set from 1999 to 2009, we identified patients with T2DM by ICD-9-CM codes 250.xx while excluding type 1 diabetes mellitus codes 250.x1 and 250.x3.28 New patients with T2DM were identified by lacking T2DM-related claims during 1999 and 2001, before the index date (the date of the first claim with the diagnosis of T2DM for each patient) of diagnosis in 2002. Patients were included in the analysis if they: (1) were at least 18 years old on the index date; (2) had a prescription for oral antihyperglycemic medications at the index date of initial diagnosis to capture the appropriate timing of initial prescriptions for new patients, as done in previous studies23; (3) had at least 1 prescription for oral antihyperglycemic medications after the second year during the study period to ensure that patients who were in the study required ongoing pharmacologic therapy; and (4) had no insulin prescriptions during any of the years in the study period because the claims data did not provide sufficient information about the insulin regimen of each patient, such as the use of a sliding-scale insulin regimen, as employed in a previous study.18 We compiled baseline information from the first year following initial diagnosis of T2DM, and we subsequently collected follow-up information for each patient over the subsequent 6 years in he analysis. As a result, a total of 11,580 patients and 69,480 patient-years were included in the analysis. The unit of analysis was patient-years.
PDF is available on the last page.